John WoolleyBA, PhD
Dr. Woolley is a Principal Investigator at the University of Liverpool, where his research group is working to identify new therapeutic strategies in leukemia and hematopoietic stem cell biology. Training initially in Ireland where his work centered on TKIs in AML and CML, he later moved to Toronto and helped identify a novel oncogene in AML and discovered its essential role in stem cell functionality.
Dr. Woolley is a founding member and academic lead of the Gene Editing Facility at the University of Liverpool. He has chaired sessions and spoken at a number of international conferences, most recently the European Hematology Association Annual Congress 2018. He has worked with a number of industry collaborators such as Beckman Coulter and BiVictrix Therapeutics. He has attained funding from numerous bodies such as the Wellcome Trust (UK) and CIHR (Canada).